Uterine Fibroids

Author/s: 
Marsh, E.E., Wegienka, G., Williams, D.R.
Date Added: 
April 23, 2024
Journal/Publication: 
JAMA
Publisher: 
JAMA
Publication Date: 
April 10, 2024
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
10.1001/jama.2024.0447

RPR Commentary

A review of current knowledge regarding uterine fibroids and what to do about them. James W. Mold, MPH

Abstract

Uterine fibroids are sex–steroid responsive benign tumors primarily composed of smooth muscle cells and extracellular matrix that develop in the wall of the uterus.1 They are one of the most common neoplasms in reproductive-aged women. Lifetime prevalence estimates in premenopausal women range from 40% to 89%, depending on the method of detection, the study population, and the ages of those studied. Fibroids can range in size from less than 1 cm to more than 20 cm. Although not all individuals with fibroids have symptoms, typical symptoms include abnormal uterine bleeding/heavy menstrual bleeding (AUB/HMB), pelvic bulk symptoms (protruding abdomen, pressure on bladder and bowels), pain, and reproductive morbidity (ie, infertility). Due to their high prevalence and associated symptoms, fibroids are the leading cause of hysterectomy in the US and account for up to $34 billion annually in direct and indirect costs.

Text Availability

Commercial full text (fees may apply)